Assay optimization and adaptation for a customized meter development
Award amount
$1,418,156Program and phase
SBIR · Phase IIAward year
2018Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- GLUCOSENTIENT INC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Z1GKW7XKS2P1
- Solicitation number
- Not reported
- Topic code
- NIAID
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Improving the effectiveness of anti-tuberculosis drugs by developing a point-of-care therapeutic drug monitoring system for areas with limited medical resources
- A point-of-care salivary cytokine test for early detection of oral cancer
- Rapid point-of-care test for hepatitis C virus (HCV) core antigen to screen active HCV infection
- Point-of-care assay using Blood Glucose Meter for early warning of chronic lung rejection
- A rapid and portable test for home monitoring of phenylalanine levels by patients with phenylketonuria using a blood glucose meter
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Manufacturing and Formulation Process Development for a Prophylactic Cholera Phage Cocktail
- A first-in-class product for the clearance of high-risk human papillomaviruses
- A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance
- Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases
- Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients
Research funding history
11 SBIR/STTR records share this UEI (2012–2024). Reported award amounts total $4,066,166. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services, National Science Foundation